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Abstract
Seprase is a homodimeric 170 kDa integral membrane gelatinase whose expression correlates with the invasiveness of
the human melanoma cell line LOX. Here, we report the molecular cloning of a cDNA that encodes the 97 kDa subunit of
seprase. Its deduced amino acid sequence predicts a type II integral membrane protein with a cytoplasmic tail of 6 amino
acids, followed by a transmembrane domain of 20 amino acids and an extracellular domain of 734 amino acids. The
 .  .carboxyl terminus contains a putative catalytic region ;200 amino acids which is homologous 68% identity to that of
 .the nonclassical serine protease dipeptidyl peptidase IV DPPIV . The conserved serine protease motif G-X-S-X-G is
present as G-W-S-Y-G. However, sequence analysis of seprase cDNA from LOX and other cell lines strongly suggests that
 .seprase and human fibroblast activation protein a FAPa are products of the same gene. We propose that sepraserFAPa
 .and DPPIV represent a new subfamily of serine integral membrane proteases SIMP . q 1997 Elsevier Science B.V.
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 .At the cell-extracellular matrix ECM interface,
invasive tumor cells elaborate extracellular ventral
membrane protrusions termed ‘invadopodia’ that ex-
hibit increased proteolytic activities at invasion foci
and thus allow metastatic cells to dissolve the sur-
w xrounding matrix 1 . We reported the identification of
a novel 170 kDa integral membrane gelatinase,
seprase, from a human malignant melanoma cell line
w xLOX 2 . This cell line had previously been shown to
have a high incidence of lung metastasis in athymic
w xmice 3 . And there appears to be a direct correlation
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between the level of seprase expression and human
melanoma invasiveness as measured by an in vitro
w xECM degradationrinvasion assay 2,4 . In a recent
study, we isolated the active enzyme from cell mem-
w xbranes and shed vesicles of LOX cells 5 . It had a
molecular mass of 170-kDa and consisted of 97-kDa
subunits that were N-glycosylated. The proteolytic
activity of seprase is associated with its dimeric form
and is completely blocked by serine-protease in-
hibitors. Sequence analysis of 3 internal proteolytic
w xfragments of the 97-kDa polypeptide 5 revealed
 .highest homology 67–88% to the 95-kDa FAPa
w x6 , an inducible cell surface glycoprotein which is
reported to be expressed on reactive stromal fibrob-
lasts of epithelial cancers and healing wounds but
0925-4439r97r$17.00 q 1997 Elsevier Science B.V. All rights reserved.
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w xwhose function is unknown 7 , and to a lower extent
 . w x33–70% with the 110-kDa subunit of DPPIV 8–11
 . w xand with 25–50% DPPX 12,13 . Herein we report
the isolation and expression of a cDNA clone that
encodes the 97 kDa subunit. Its deduced amino acid
sequence confirms that seprase, like DPPIV, is a
member of the family of nonclassical serine hydro-
w xlases 8–17 . Additionally, based on cDNA sequence
analysis of LOX and other cell lines we propose that
seprase and FAPa are products of the same gene.
We carried out RT-PCR of LOX and human WI-38
fibroblast total RNA using 3 oligonucleotide primer
pairs that correspond to the cDNA sequence of hu-
man FAPa GenBank accession no. U09278; Fig.
. 1A . The resulting 3 amplicons 825, 1265 and 1468
. Xbp are overlapping and extend from the 5 UTR
 . X  .FAP 1; nt 161 to the 3 UTR FAP 6; nt 2523 thus
encoding the complete FAPa ORF. No difference
was seen in the number or size of the cDNA ampli-
cons generated from LOX and WI-38 RNA. There-
fore, to synthesize putative full length seprase cDNA,
RT-PCR of LOX RNA utilizing the primer pair FAP
 X X .1 5 CCACGCTCTGAAGACAGAATT 3 ; sense
 X Xand FAP 6 5 TCAGATTCTGATACAGGCT 3 ; an-
.tisense was carried out. The resultant ;2.4 kb
amplicon was subcloned into the pCR3.1 mammalian
 . w xexpression vector Invitrogen 5 .
To determine whether this amplicon encoded
seprase, we transiently transfected COS-7 cells with
 .the above mentioned recombinant plasmid pA15 ,
 .the vector pA11 , and an expression plasmid
 . w xpCD26 containing human DPPIV cDNA 10 . We
w xused the antiseprase mAb, D8 4 , and a class matched
 .  .IgG2a antiDPPIV mAb, F4 negative control , for
detection of seprase surface expression. As can be
seen in Fig. 1B, the antiseprase mAb specifically
stained cells that had been transfected with pA15
 .Fig. 1B1 but the D8 mAb did not stain the pCD26
 .transfected cells Fig. 1B2 . In addition, the F4 mAb
 .did not stain pA15 transfectants Fig. 1B3 but did
 .stain the pCD26 transfectants Fig. 1B4 . Detergent
extracts were prepared from pA15 and pA11 tran-
siently transfected COS-7 cells and Western Blot
 . analysis was performed Fig. 1C . Western blots Fig.
.  .1C, Lanes 1–6 of dimeric seprase 170 kDa utiliz-
w xing the antiseprase mAbs D8 and D28 4 show that
 .the pA15 transfected cells Fig. 1C, Lanes 2 and 5
express a seprase band that is also present in the
 .control LOX cell extract Fig. 1C, Lanes 1 and 4 but
at markedly lower endogenous levels in the pA11
 .transfected cells Fig. 1C, Lanes 3 and 6 . The speci-
ficity of the antiseprase mAbs in these blots was
 .confirmed using a class matched IgG2a negative
 .control mAb B5 Fig. 1C, Lanes 7–9 . Likewise, the
mAb D8 in the Western blot of denatured seprase 97
.kDa detects comigrating bands for the LOX and
 .pA15 extracts Fig. 1C, Lanes 10 and 11 and a
markedly lower intensity band for the mock trans-
 .fected lysate Fig. 1C, Lane 12 . The specificity of
the D8 mAb for denatured seprase was also con-
firmed by the negative control mAb B5 Lanes 13–
.15 . Importantly, we have also detected the expres-
sion of seprase proteolytic activity in pA15 tran-
siently transfected COS-7 cell detergent lysates which
w xis reported elsewhere 5 . In these experiments func-
 .tional dimeric seprase 170 kDa as determined by
gelatin zymography was detected in the pA15 trans-
 .fectants but not in the mock pA11 transfected cells.
Sequence analysis of the cDNA insert of pA15
 .Accession number U76833 revealed an ORF of
2280 bp which encodes a polypeptide of 760 amino
 .acids with a M 87 722 Fig. 2 . The cDNA sequencer
predicts a type II integral membrane protein with a
 .short cytoplasmic tail 6 amino acids followed by a
 .hydrophobic transmembrane domain 20 amino acids
and a relatively large extracellular domain composed
of 734 amino acids. Three internal peptides generated
w xby Lys C digestion of the 97 kDa subunit 5 yielded
10, 12 and 8 amino acid residues from sequence
analysis of their N-termini that correspond to amino
 . 220 229 acid positions Fig. 2 Phe to Thr 80% iden-
. 461 472  . 510tity , Tyr to Pro 67% identity and Lys to
517  .Thr 88% identity , respectively. Importantly, se-
quence analysis of 5 additional LOX seprase cDNA
 .clones all generated by RT-PCR in the regions
corresponding to the peptide sequence data confirm
the pA15 sequence. In addition, the cDNA sequence
indicates that Phe220, Tyr 461 and Lys510 are all pre-
ceded by a Lys residue and that the deduced amino
acid sequence identity between seprase and FAPa in
the regions corresponding to the 3 peptides are 90,
100 and 100%, respectively. There are 6 potential
N-glycosylation sites: 5 of the sites are clustered in a
membrane proximal region extending from Asn49 to
Asn314 with the sixth site, Asn679, located in the
 .putative catalytic region see below . There are 12
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cysteine residues: 7 of these residues are clustered in
a region that extends from Cys305 to Cys466. Located
at the carboxyl terminus is a putative catalytic region
consisting of ;200 amino acids that extends from
Tyr 560 to Asp760. Within this region is the catalytic
triad of residues Ser624, Asp702 and His734 which are
w xin a nonclassical sequence orientation 14–16 . The
consensus motif Gly-X-Ser-X-Gly which is character-
istic of serine proteases is conserved around Ser624.
A comparison of the nucleotide sequence of the
w xpA15 cDNA to that for FAPa 6 indicated a differ-
ence of 8 base pairs in the ORF of their respective
 .cDNAs Fig. 2 . There are 5 base substitutions: 3
give rise to nonconservative amino acid substitutions
 .  .at residues a207 Pro to Ala , a229 Lys to Thr and
 .a354 Arg to Thr , respectively. Five additional LOX
seprase cDNA clones produced from 3 RNA prepa-
.rations have identical nucleotide sequences to pA15
at the 3 amino acid substitution positions. The fourth
and fifth substitutions are silent corresponding to
 .Fig. 1. A RT-PCR of LOX and WI-38 fibroblast RNA. Total
 .  . RNA 6 mg from LOX Lanes 1, 3, 5 and 7 and WI-38 Lanes
.2, 4, 6 and 8 was screened for the presence of sepraserFAPa
 .mRNA Lanes 1–6 and glyceraldehyde 3-phosphate dehydroge-
 .  .nase G3PDH mRNA Lanes 7, 8 . Lanes 1–6 utilized primers
w xthat correspond to the FAPa cDNA sequence 6 . Lanes 1 and 2:
X X . X5 CCACGCTCTGAAGACAGAATT 3 FAP 1; sense q5
X .GATTCTTAGCTCCAGCCT 3 FAP 2; antisense nt 161 to nt
X X986. Lanes 3 and 4: 5 TTACATCTATGACCTTAGCA 3 FAP
. X X11; sense q5 ACAGACCTTACACTCTGAC 3 FAP 4; anti-
. Xsense nt 598 to nt 1863. Lanes 5 and 6: 5 CCAGCAAT-
X . XGATAGCCTCAA 3 FAP 3; sense q5 TCAGATTCTGAT-
X  .ACAGGCT 3 FAP 6; antisense nt 1055 to nt 2523. FAP 1 and
FAP 6 correspond to sequences within the 5X UTR and 3X UTR,
respectively. Lanes 7 and 8 utilized the human G3PDH control
 .amplimer set Clontech . Samples were electrophoresed on a 1%
 .agarose gel. B COS-7 cells transiently transfected with pA15
express seprase. Immunostaining of COS-7 cells that were tran-
siently transfected with recombinant plasmids containing seprase
 .  . w xpA15 and human DPPIV pCD26 10 cDNA were stained
 .with the antiseprase mAb D8 and the class matched IgG2a
antiDPPIV mAb F4. 1: pA15 transfected cells stained with D8. 2:
pCD26 transfected cells stained with D8. 3: pA15 transfected
cells stained with F4. 4: pCD26 transfected cells stained with F4.
Primary mAbs D8 and F4 were detected by the StrAviGen
 .  .Multilink Detection System and AEC substrate BioGenex . C
 .Detection of pA15 encoded dimeric 170 kDa and monomeric
 .97 kDa seprase. Western blot analysis was carried out on
 .detergent extracts of pA15 and pA11 mock transiently trans-
fected COS-7 cells and on LOX cell extract that was purified by
 . w xwheat germ agglutinin WGA column chromatography 2 using
 . the antiseprase mAbs D8 Lanes 1–3, 10–12 and D28 Lanes
.  .4–6 and the class matched IgG2a negative control mAb B5
 .Lanes 7–9; 13–15 . Detergent extract samples were either not
 .heated before undergoing SDS-PAGE 170 kDa in Lanes 1–9 or
 .heated at ;1008C for 5 min 97 kDa in Lanes 10–15. Lanes 1,
4, 7, 10, 13: WGA purified LOX extract. Lanes 2, 5, 8, 11, 14:
pA15 transfected cell extract. Lanes 3, 6, 9, 12, 15- pA11
transfected cell extract. Detergent extract samples were resolved
by 10% SDS-PAGE and transferred to Optitran nitrocellulose
 .membranes Schleicher and Schuell .
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 . nucleotide positions a252 A to G and a2124 A to
.G , respectively. Analysis of 6 additional LOX clones
all revealed an A nucleotide at position a252. At
nucleotide position a2124, 5 of 7 additional LOX
clones are in agreement with pA15. The remaining
difference of 3 bp is due to the insertion of 3 guanine
Fig. 2. Nucleotide and deduced amino acid sequences for the coding region of pA15. Nucleotide and amino acid sequence numbers are
shown to the right. The putative transmembrane region is represented in bold characters. Potential N-glycosylation sites are shown as
w xbold italicized characters. Nucleotide substitutions and insertions relative to the FAPa cDNA sequence 6 are underlined. Amino acids
w xdetermined by sequence analysis of 3 internal peptides generated by Lys C digestion of the 97 kDa subunit 5 are underlined. The
 624 702 734.putative catalytic triad of seprase Ser , Asp , His and its serine protease consensus motif are represented by bold underlined
characters.
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 .  . w xFig. 3. Alignment of deduced amino acid sequences for seprase SEP.PRO , human FAPa FAP.PRO 6 , Xenopus fibroblast activation
 . w x  . w x  . w xfactor alpha FFAF.PRO 17 , human DPPIV HUMDPP1.P 10 and human DPPX-S HUMDPPX.P 13 using the Lasergene software
 .Megalign program DNASTAR . Identical residues are boxed. Sequence gaps are indicated by dashed lines. Amino acid sequence
numbers for each protein are shown to the left.
nucleotides at positions a1876 or 1877, 1879 or 1880
and 2010 in the pA15 cDNA. The nucleotide se-
quence from nucleotide a1876-G to a2010-G en-
codes a contiguous sequence of 45 amino acids ex-
tending from Gly 626 to Lys670 in the putative cat-
 .alytic region Fig. 2 . We have sequenced the region
that encodes the putative catalytic region of seprase
in 9 additional LOX seprase cDNA clones including
.2 clones from a lambda gt11 library and 4 cDNA
clones from cell lines other than LOX, including one
 626clone from the WI-38 fibroblast cell line Gly to
Lys670 is identical to the pA15 sequence in this
.  .clone , also MDA-MB-436 a breast carcinoma line ,
 .RPMI7951 a melanotic melanoma line and a clone
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 .Fig. 3. continued .
from human umbilical vein smooth muscle. All ex-
hibit the insertion of 3 guanine nucleotides that corre-
spond with the pA15 sequence. Thus, the difference
of 8 bp between the seprase and FAPa cDNAs gives
rise to a total difference of 48 amino acids in their
deduced amino acid sequences or an identity of ;
94%. The significance of the 3 nonconservative amino
acid substitutions remains to be determined. The
 .substitution at position a229 Lys to Thr generates a
 .potential N-glycosylation site in seprase see below .
However, the 3 guanine nucleotide insertions in the
pA15 cDNA result in a significant divergence of the
 .amino acid sequence 45 contiguous residues in the
 .putative catalytic region Fig. 3; see below . Impor-
tantly, the consensus sequence motif Gly-X-Ser-X-
Gly which is identical in seprase and the related
 .mammalian protease DPPIV Gly-Trp-Ser-Tyr-Gly
w xis reported to be Gly-Trp-Ser-Tyr-Glu in FAPa 6 .
The substitution of Gly 626 with Glu in the reported
FAPa cDNA sequence is significant since it has been
shown that substitution of this Gly residue in rat
DPPIV results in complete loss of proteolytic activity
w x18 and that this mutant is retained and degraded in
w xthe endoplasmic reticulum 19,20 .
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Seprase is also homologous to the recently re-
ported Xenopus lae˝is homologue of human FAPa
w x17 . It exhibits a 58% amino acid identity with the
Xenopus homologue which increases to 67% in the
 .putative catalytic region Fig. 3 . Five of the 6 N-
glycosylation sites present in seprase are conserved in
this FAPa homologue including the site at Asn227
that is reported not to be present in human FAPa .
Seven Cys residues are conserved between seprase
and the Xenopus homologue including 6 of 7 Cys
residues present in the seprase Cys rich region. Im-
portantly, the Xenopus fibroblast factor is highly
homologous 70% nucleotide identity; 62% amino
. 626 670acid identity to seprase in the Gly to Lys
 .region Fig. 3; see above . Conversely, the amino
acid identity in this region between the reported
sequence for human FAPa and its Xenopus homo-
logue is 18% although the nucleotide identity is 69%.
Both seprase and the Xenopus FAPa homologue
have the same serine protease consensus motif Gly-
.Trp-Ser-Tyr-Gly .
In addition to FAPa , there is also a striking se-
quence identity with the multifunctional exopeptidase
w xDPPIV 8–11 . Like seprase, this serine protease is
homodimeric consisting of 2 subunits with a Mr
110 000 to 130 000 that must be associated for activ-
w xity 21,22 . However, they have different substrate
w xspecificities 2,5,9 . Both are type II integral mem-
brane proteins that have a short cytoplasmic tail
consisting of 6 amino acids followed by a transmem-
brane domain of 20 amino acids for seprase and 22
for DPPIV. The extracellular domain of both pro-
teases, 734 and 738 amino acids for seprase and
DPPIV, respectively, can be divided into an N-glyco-
sylated membrane proximal region; a central region
that is rich in Cys residues; and a carboxyl terminal
region which contains the catalytic triad in the non-
w xclassical orientation 14–16 . The sequence identity
w xbetween seprase and human DPPIV 10 is 52%.
However, in the putative catalytic region the identity
 .increases to 68% Fig. 3 . The N-glycosylation and
Cys rich regions are 49% and 47%, respectively.
Four of six potential N-glycosylation sites in seprase
are conserved in DPPIV; however, DPPIV has five
additional N-glycosylation sites. Both have 12 Cys
with 6 residues being conserved in the Cys rich
region and 3 in the catalytic region. Within the ‘stalk’
segment that consists of the 20 amino acids that
immediately follow the transmembrane domain there
is only a 15% identity. This region is reported to
show the greatest divergence in sequence among
w xDPPIV-like proteins 14 . In addition, only 4 residues
 .are conserved in the transmembrane domain 20%
but 4 of 6 amino acids in the cytoplasmic tail of both
proteins are conserved.
Seprase also exhibits a 32% amino acid identity
 .with human DPPX DPPX short form-DPPX-S , a
DPPIV related integral membrane protein of un-
known function which is predominantly expressed in
w xmammalian brain 6,12,13 . Dipeptidyl peptidase X
lacks the catalytic Ser residue present in the other
 .DPPIV related proteins Fig. 3 . Interestingly, the 6
Cys residues that are conserved between seprase and
DPPIV in the Cys rich region are also conserved in
DPPX and 2 of 3 Cys residues located in the catalytic
region of seprase and DPPIV are conserved in DPPX.
Two potential N-glycosylation sites present in seprase
at Asn227 and Asn314 are also present in DPPIV and
DPPX as well as Asp and Gly residues that corre-
spond to Asp599 and Gly 626 in seprase. These residues
have been reported to be required for the transport of
w x w xmouse 23 and rat DPPIV 19,20 to the cell surface,
respectively.
The results from immunostaining, Western blot
w xand gelatin zymography 5 analyses of transiently
transfected COS-7 cells confirm that pA15 encodes
the 170 kDa integral membrane protease originally
w xdescribed by Aoyama and Chen 2 . Also, our work
confirms the peptide sequence data obtained from the
97 kDa subunit which indicated that seprase exhib-
w xited highest homology with human FAPa 5 . Se-
quence data from pA15 and several additional cDNA
 .clones 13 total from LOX and other cell lines
including the fibroblast line WI-38 strongly suggests
that seprase and FAPa are the same protein and thus
products of the same gene. This conclusion is sup-
ported by the RT-PCR data obtained with FAPa
 .primers for LOX and WI-38 RNA Fig. 1A . The
possibility that seprase and FAPa represent alterna-
tively spliced variants that diverge in their putative
catalytic regions seems unlikely based on the ge-
w x w xnomic organization of the human 24 and mouse 25
DPPIV genes. The exon-intron structure of the DP-
PIV genes predicts that the genomic sequence which
encodes the region of divergence in seprase and
 626 670.FAPa Gly to Lys is contained within 2 con-
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 .tiguous exons exon 22 and 23 but the divergence in
sequence does not align with the exon-intron junc-
tions for these exons. Additionally, the high degree of
 .sequence identity 80% and the lack of any inser-
tions or deletions of amino acids in the cDNA se-
quences of seprase and human DPPIV in the region
encoded by exons 22 and 23 suggests that no intron-
w xexon junction sliding 26,27 has occurred between
the DPPIV and seprase genes in this region. Also,
except for the 3 missing guanine nucleotides, the
nucleotide sequence that encodes the Gly 626 to Lys670
 .region nt 1876-G to nt 2010-G; Fig. 2 is identical in
both seprase and FAPa cDNAs. Thus, we propose
that sepraserFAPa and DPPIV represent novel pro-
teases within the nonclassical serine hydrolase fam-
ily. Namely, serine integral membrane proteases
 .SIMP with similar structural organizations and
membrane topologies that require subunit dimeriza-
w xtion for activation of proteolytic activity 5,21,22 .
Multiple nonproteolytic functions have been ascribed
w xto DPPIV 9,28–31 . It is interesting to speculate
whether this DPPIV related protein, sepraserFAPa ,
may function in roles other than as an integral mem-
brane protease. The isolation of the seprase cDNA
should help elucidate what the precise role of this
protein is in cancer metastasis.
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